Idarubicin 中文名称: 伊达比星

别名: 伊达比星;依达比星;4-去甲氧基柔红霉素;伊达吡星; 盐酸伊达比星;盐酸伊达比星 Idarubicin HCl

目录号: V44705 纯度: ≥98%

COA 产品数据产品说明书 SDS

Idarubicin 是一种口服生物活性蒽环类抗白血病药物。

Idarubicin CAS号: 58957-92-9
产品类别: New3

产品仅用于科学研究，不针对患者销售

规格	价格
500mg
1g
Other Sizes

大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Idarubicin:

盐酸依达比星

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Idarubicin 是一种口服生物活性蒽环类抗白血病药物。 Idarubicin 抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。 Idarubicin 会引起 DNA 损伤。 Idarubicin 抑制 DNA 合成和 c-myc 表达。伊达比星还抑制细菌和酵母的生长。

生物活性&实验参考方法

体外研究 (In Vitro)	伊达比星在 MCF-7 单层细胞中的半衰期 (IC50) 为 3.3 ± 0.4 ng/mL，但在多细胞球体中为 7.9 ± 1.1 ng/mL [1]。在许多体外系统中，发现伊达比星比柔红霉素或多柔比星具有更强的细胞毒性。这是因为伊达比星具有触发拓扑异构酶 II 介导的 DNA 断裂形成的卓越能力 [2]。伊达比星的活性大约比表柔比星和阿霉素高 25 倍，分别为 57.5 倍 [3]。伊达比星的 IC50 约为 0.01 μM，以浓度依赖性方式抑制 MCF-7 细胞增殖。 Idarubicin 以浓度依赖性以及时间和浓度依赖性方式抑制 c-myc 表达 [4]。
药代性质 (ADME/PK)	吸收、分布和排泄该药物主要通过胆汁排泄，少量通过肾脏排泄，主要以伊达比星醇的形式排出。生物半衰期 22 小时
毒性/毒理 (Toxicokinetics/TK)	蛋白质结合 97%
参考文献	[1]. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7. [2]. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88. [3]. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70. [4]. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-. [5]. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3.
其他信息	伊达比星是一种单糖衍生物，属于蒽环类抗生素和脱氧己糖苷。它来源于并四苯的氢化物。它是一种口服蒽环类抗肿瘤药物。该化合物已显示出对乳腺癌、淋巴瘤和白血病的活性，并具有降低心脏毒性的潜力。伊达比星是一种蒽环类拓扑异构酶抑制剂。伊达比星的作用机制是作为拓扑异构酶抑制剂。伊达比星是抗肿瘤蒽环类抗生素柔红霉素的半合成4-去甲氧基类似物。伊达比星可嵌入DNA并干扰拓扑异构酶II的活性，从而抑制DNA复制、RNA转录和蛋白质合成。由于其高亲脂性，伊达比星比其他蒽环类抗生素化合物更有效地穿透细胞膜。一种口服蒽环类抗肿瘤药物。该化合物已显示出对乳腺肿瘤、淋巴瘤和白血病的活性。另见：盐酸伊达比星（有盐形式）。药物适应症用于治疗成人急性髓系白血病 (AML)。这包括法美英 (FAB) 分类的 M1 至 M7 类药物。作用机制伊达比星通过多种已提出的作用机制发挥抗有丝分裂和细胞毒活性：伊达比星通过嵌入碱基对之间与 DNA 形成复合物，并通过稳定 DNA-拓扑异构酶 II 复合物来抑制拓扑异构酶 II 的活性，从而阻止拓扑异构酶 II 催化的连接-再连接反应中的再连接部分。药效学伊达比星是一种蒽环类抗肿瘤药物。此类药物的一般特性包括：以多种不同的方式与 DNA 相互作用，包括嵌入（挤压在碱基对之间）、DNA 链断裂以及抑制拓扑异构酶 II。大多数此类化合物是从天然来源和抗生素中分离得到的。然而，蒽环类药物缺乏抗菌抗生素的特异性，因此会产生显著的毒性。蒽环类药物是目前最重要的抗肿瘤药物之一。阿霉素广泛用于治疗多种实体瘤，而柔红霉素和伊达比星则专门用于治疗白血病。伊达比星还可以抑制聚合酶活性，影响基因表达调控，并产生自由基损伤DNA。伊达比星对多种肿瘤（包括移植瘤和自发瘤）均具有抗肿瘤作用。蒽环类药物不具有细胞周期特异性。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C26H27NO9
精确质量	497.168
CAS号	58957-92-9
相关CAS号	Idarubicin hydrochloride;57852-57-0
PubChem CID	42890
外观&性状	Typically exists as solid at room temperature
密度	1.6±0.1 g/cm3
沸点	725.4±60.0 °C at 760 mmHg
闪点	392.5±32.9 °C
蒸汽压	0.0±2.5 mmHg at 25°C
折射率	1.706
LogP	2.95
tPSA	176.61
氢键供体(HBD)数目	5
氢键受体(HBA)数目	10
可旋转键数目(RBC)	3
重原子数目	36
分子复杂度/Complexity	912
定义原子立体中心数目	6
SMILES	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=O)C5=CC=CC=C5C4=O)C(=C32)O)O)(C(=O)C)O)N)O
InChi Key	XDXDZDZNSLXDNA-TZNDIEGXSA-N
InChi Code	InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
化学名	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)	注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。注射用配方 (IP/IV/IM/SC等) 注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline) 生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。注射用配方 2:* DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。 View More 注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。注射用配方 5:* 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline) 注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline) 注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) 注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil) 注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 口服配方口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。 View More 口服配方 3: 溶解于 PEG400 (聚乙二醇400) 口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 6: 做成粉末与食物混合注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

溶解度 (体内实验)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

注射用配方
(IP/IV/IM/SC等)

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
CTID: NCT02310321
Phase: Phase 1/Phase 2 Status: Completed
Date: 2024-11-29

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
CTID: NCT03117751
Phase: Phase 2/Phase 3 Status: Active, not recruiting
Date: 2024-11-26

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
CTID: NCT03226418
Phase: Phase 2 Status: Completed
Date: 2024-11-15

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
CTID: NCT03214562
Phase: Phase 1/Phase 2 Status: Recruiting
Date: 2024-11-12

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
CTID: NCT02339740
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-11-07

View More

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
CTID: NCT02236013
Phase: Phase 1 Status: Completed
Date: 2024-11-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
CTID: NCT04375631
Phase: Phase 1 Status: Recruiting
Date: 2024-11-04

Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
CTID: NCT02185768
Phase: Phase 2 Status: Completed
Date: 2024-10-15

Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
CTID: NCT02881086
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-10-10

Venetoclax + Decitabine vs. '7+3' Induction Chemotherapy in Young AML
CTID: NCT05177731
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-10-03

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
CTID: NCT00801489
Phase: Phase 2 Status: Recruiting
Date: 2024-09-20

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CTID: NCT06001788
Phase: Phase 1 Status: Recruiting
Date: 2024-08-29

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
CTID: NCT02096055
Phase: Phase 2 Status: Completed
Date: 2024-08-27

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
CTID: NCT02416388
Phase: Phase 2/Phase 3 Status: Recruiting
Date: 2024-08-07

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
CTID: NCT02632708
Phase: Phase 1 Status: Active, not recruiting
Date: 2024-07-25

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
CTID: NCT06034470
Phase: Phase 1 Status: Recruiting
Date: 2024-07-18

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
CTID: NCT02400281
Phase: Phase 1/Phase 2 Status: Completed
Date: 2024-07-03

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
CTID: NCT04047641
Phase: Phase 1/Phase 2 Status: Recruiting
Date: 2024-06-20

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
CTID: NCT03164057
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-05-29

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
CTID: NCT03860844
Phase: Phase 2 Status: Terminated
Date: 2024-05-16

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
CTID: NCT03589729
Phase: Phase 2 Status: Recruiting
Date: 2024-05-08

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
CTID: NCT02115295
Phase: Phase 2 Status: Recruiting
Date: 2024-04-25

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
CTID: NCT04778397
Phase: Phase 3 Status: Terminated
Date: 2024-04-15

Auto BMT for Non-M3 AML in 1st Remission in Pts CTID: NCT00534469
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-04-02

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
CTID: NCT02135874
Phase: Phase 2 Status: Completed
Date: 2024-03-22

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
CTID: NCT04801797
Phase: Phase 2 Status: Recruiting
Date: 2024-03-18

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
CTID: NCT06050941
Phase: Phase 2 Status: Not yet recruiting
Date: 2024-03-05

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
CTID: NCT02013648
Phase: Phase 3 Status: Completed
Date: 2024-02-23

Allogeneic Hema
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
CTID: null
Phase: Phase 3 Status: Completed
Date: 2017-06-19

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
CTID: null
Phase: Phase 3 Status: Completed
Date: 2017-03-17

A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
CTID: null
Phase: Phase 3 Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2016-04-20

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
CTID: null
Phase: Phase 3 Status: Completed
Date: 2015-05-29

Study Protocol LAM 2013/01
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2015-02-04

An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE)
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-08-18

A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation.
CTID: null
Phase: Phase 3 Status: Ongoing, Completed
Date: 2014-06-18

National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2014-05-20

Tratamiento de la leucemia mieloide aguda de novo con la combinación de idarrubicina en dosis creciente, citarabina y sensibilización (?priming?) con G-CSF. Estudio prospectivo en fase I/II de toxicidad y eficacia
CTID: null
Phase: Phase 1, Phase 2 Status: Ongoing
Date: 2012-05-21

Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA)
CTID: null
Phase: Phase 1, Phase 2 Status: Completed
Date: 2011-12-02

Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2011-10-26

Multicentric, prospective, open-label, of one group and phase I-II clinical trial to analyze induction treatment with a combination of fludarabine, idarubicin, cytarabine, G-CSF and plerixafor for the treatment of young patients with recurring or resistant AML.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2011-09-23

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
CTID: null
Phase: Phase 2 Status: Completed
Date: 2010-10-11

Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study
CTID: null
Phase: Phase 3 Status: Completed
Date: 2010-05-04

An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen.
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2009-12-18

TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2009-07-16

CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults
CTID: null
Phase: Phase 3 Status: Completed
Date: 2009-02-01

A Randomized Phase II Study of
CTID: null
Phase: Phase 2 Status: Completed
Date: 2009-01-20

INDUCTION, CONSOLIDATION AND INTENSIFICATION PROTOCOL FOR PATIENTS YOUNGER THAN 66 YEARS WITH PREVIOUSLY UNTREATED CD33 POSITIVE ACUTE MYELOID LEUKEMIA (AML)
CTID: null
Phase: Phase 2 Status: Completed
Date: 2008-05-29

A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promyelocytic leukemia
CTID: null
Phase: Phase 3 Status: Completed
Date: 2007-07-10

A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy
CTID: null
Phase: Phase 1, Phase 2 Status: Completed
Date: 2007-06-22

A phase III trial in adult acute myelogenous leukemia AML comparing 1 standard-dose versus high-dose remission induction therapy and 2 , within a risk-oriented postremission strategy, an autologous blood stem cell transplantation versus an autologous blood stem cell-supported multicycle high-dose program Protocol NILG-AML 02/06 .
CTID: null
Phase: Phase 3 Status: Completed
Date: 2006-09-11

Treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence
CTID: null
Phase: Phase 3 Status: Completed
Date: 2005-12-23

Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease
CTID: null
Phase: Phase 3 Status: Completed
Date: 2004-11-08

Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreated AML: a randomized phase III trial (AML- 17) of the EORTC-LG and the GIMEMA-ALWP.
CTID: null
Phase: Phase 3 Status: Completed
Date: 2004-07-30
Post remission therapy with arsenic trioxide and gemtuzumab ozogamicin in acute promylocytic leukemia, a phase II study (JALSG APL212 Study)
CTID: UMIN000008470
Phase: Phase II Status: Recruiting
Date: 2012-07-19

Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-R11: Multi-center Phase II Study of the efficacy and the safety in the induction chemotherapy containing fludarabine for children with the first bone marrow relapse and induction failure of acute myeloid leukemia.
CTID: UMIN000007390
Phase: Phase II Status: Complete: follow-up complete
Date: 2012-03-01